Eradivir’s mission is to develop and commercialize a platform technology that will successfully treat respiratory viruses and other infectious diseases. Eradivir’s lead drug EV25 for influenza addresses the shortcomings of current treatments by integrating a potent immunotherapy into an FDA-approved inhibitor. By linking the influenza drug zanamivir to two antibody-recruiting molecules, a small molecule drug is created that first binds to free viruses and virus-infected cells then recruits naturally occurring antibodies to coat these viruses/cells, leading to their rapid removal by the immune system. Eradivir’s drug EV25 also retains the antiviral mechanism of zanamivir by inhibiting the virus’s reproductive process.  These two mechanisms render it difficult for resistant virus strains to emerge. Eradivir is excited to begin clinical trials in October 2024.   


Coalition to Stop Flu Chairman Former Sen. Tom Daschle Quoted in Endpoints News

National Academy of Medicine: “An effective pandemic preparedness and response system is possible”